Jillian M. McClain

Jillian M. McClain supports the National Heart, Lung, and Blood Institute (NHLBI) in executing mission-critical procurement strategies aligned with advancing biomedical research in cardiovascular, pulmonary, hematologic, and sleep disorders. Though her formal title is not listed, her procurement activities center on acquiring analytical laboratory instrumentation, specialized research services, and biologic data infrastructure essential to precision medicine and single-cell genomics initiatives. She manages complex acquisitions under FAR and NIH-specific guidelines, ensuring compliance with scientific rigor and federal procurement standards while facilitating access to cutting-edge technologies for NIH-funded investigators. McClain maintains consistent relationships with key institutional partners including the University of Mississippi Medical Center, Wake Forest University Health Sciences, and TDA Research, Inc., reflecting a preference for academic medical centers and innovative small technology firms. Her contracting patterns emphasize long-term, science-driven partnerships rather than transactional vendor relationships, often supporting multi-year research service agreements and specialized equipment procurement. These collaborations are strategically aligned with NHLBI’s need for high-complexity, low-volume solutions requiring deep domain expertise in biologic assay development and diagnostic instrumentation. Her procurement portfolio shows a strong preference for open competition, with 95.2% of awards issued without set-aside designations, indicating a focus on technical merit and capability over socioeconomic classifications. While small business participation is present at 4.8%, it is selectively applied, suggesting a prioritization of scientific outcome over socioeconomic targets unless explicitly aligned with mission needs. McClain’s primary NAICS focus includes 541611 (administrative and management consulting services for research operations), 334516 (analytical laboratory instrument manufacturing), and 325413 (in-vitro diagnostic substance manufacturing). She routinely procures next-generation sequencing platforms, flow cytometers, biospecimen management systems, and bioinformatics infrastructure, demonstrating deep technical familiarity with the tools underpinning modern molecular and translational research at NHLBI.